|Table of Contents|

Redefining the value of hormonal therapy in endometrial cancer in the era of molecular classification

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
1-6
Research Field:
Publishing date:

Info

Title:
Redefining the value of hormonal therapy in endometrial cancer in the era of molecular classification
Author(s):
ZHAO Shuangshuang1; 2; WANG Boning1; 2; WANG Yingmei1; 2
1.Department of Gynecology and Obstetrics,Tianjin Medical University General Hospital,Tianjin 300052,China;2.Tianjin Key Laboratory of Female Reproductive Health and Eugenics,Tianjin 300052,China.
Keywords:
endometrial cancer; hormonal therapy; molecular classification; hormone receptor
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2025.01.001
Abstract:
Endometrial cancer is one of the most common gynecological cancers,with an annually increasing incidence rate and a trend of harassing younger women than before.The introduction of molecular classification has overcome the limitations of the traditional Bokhman division,facilitating precise diagnosis,risk stratification,and targeted therapy of endometrial cancer by exploring molecular features.In the era of molecular classification,hormone therapy,as a traditional treatment characterized by low toxicity,high cost-effectiveness,and high patient compliance,should be redefined for the value.

References:

［1］CROSBIE EJ,KITSON SJ,MCALPINE JN,et al.Endometrial cancer［J］.Lancet,2022,399(10333):1412-1428.
［2］BOKHMAN JV.Two pathogenetic types of endometrial carcinoma［J］.Gynecologic Oncology,1983,15(1):10-17.
［3］CANCER GENOME ATLAS RESEARCH N,KANDOTH C,SCHULTZ N,et al.Integrated genomic characterization of endometrial carcinoma［J］.Nature,2013,497(7447):67-73.
［4］KOMMOSS S,MCCONECHY MK,KOMMOSS F,et al.Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series［J］.Annals of Oncology,2018,29(5):1180-1188.
［5］STELLOO E,NOUT RA,OSSE EM,et al.Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts［J］.Clinical Cancer Research,2016,22(16):4215-4224.
［6］VAN WEELDEN WJ,REIJNEN C,KUSTERS-VANDEVELDE HVN,et al.The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited:a European Network for Individualized Treatment of Endometrial Cancer collaboration study［J］.Human Pathology,2021,109:80-91.
［7］TRAVAGLINO A,RAFFONE A,MOLLO A,et al.TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma［J］.Archives of Gynecology and Obstetrics,2020,301(5):1117-1125.
［8］REIJNEN C,VREDE SW,EIJKELENBOOM A,et al.Pure and mixed clear cell carcinoma of the endometrium:A molecular and immunohistochemical analysis study［J］.Cancer Med,2023,12(11):12365-12376.
［9］LU KH,BROADDUS RR.Endometrial cancer［J］.New England Journal of Medicine,2020,383(21):2053-2064.
［10］URICK ME,BELL DW.Clinical actionability of molecular targets in endometrial cancer［J］.Nature Reviews Cancer,2019,19(9):510-521.
［11］DECRUZE SB,GREEN JA.Hormone therapy in advanced and recurrent endometrial cancer:a systematic review［J］.International Journal of Gynecological Cancer,2007,17(5):964-978.
［12］CARLSON MJ,THIEL KW,LESLIE KK.Past,present,and future of hormonal therapy in recurrent endometrial cancer［J］.International Journal of Women's Health,2014,6:429-435.
［13］KISTNER RW.Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium［J］.Cancer,1959,12:1106-1122.
［14］KELLEY RM,BAKER WH.Progestational agents in the treatment of carcinoma of the endometrium［J］.New England Journal of Medicine,1961,264:216-222.
［15］STEINER GJ,KISTNER RW,CRAIG JM.Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium-further observations［J］.Metabolism:Clinical and Experimental,1963,14:356-386.
［16］LENTZ SS,BRADY MF,MAJOR FJ,et al.High-dose megestrol acetate in advanced or recurrent endometrial carcinoma:a Gynecologic Oncology Group Study［J］.Journal of Clinical Oncology,1996,14(2):357-361.
［17］THIGPEN JT,BRADY MF,ALVAREZ RD,et al.Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma:a dose-response study by the Gynecologic Oncology Group［J］.Journal of Clinical Oncology,1999,17(6):1736-1744.
［18］PODRATZ KC,O' BRIEN PC,MALKASIAN GD,et al.Effects of progestational agents in treatment of endometrial carcinoma［J］.Obstetrics and Gynecology,1985,66(1):106-110.
［19］MILESHKIN L,EDMONDSON R,O'CONNELL RL,et al.Phase 2 study of anastrozole in recurrent estrogen(ER)/progesterone (PR) positive endometrial cancer:The PARAGON trial-ANZGOG 0903［J］.Gynecologic Oncology,2019,154(1):29-37.
［20］LINDEMANN K,MALANDER S,CHRISTENSEN RD,et al.Examestane in advanced or recurrent endometrial carcinoma:a prospective phase Ⅱ study by the Nordic Society of Gynecologic Oncology(NSGO)［J］.BMC Cancer,2014,14:68.
［21］CONCIN N,MATIAS-GUIU X,VERGOTE I,et al.ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma［J］.International Journal of Gynecological Cancer,2021,31(1):12-39.
［22］VAN WEELDEN WJ,BRETVELD R,ROMANO A,et al.Trends over time in the incidence and use of hormonal therapy in endometrial cancer:a population-based study in the Netherlands［J］.International Journal of Gynecological Cancer,2021,31(7):1014-1020.
［23］THIGPEN JT,BLESSING JA,DISAIA PJ,et al.A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma:A Gynecologic Oncology Group study［J］.Journal of Clinical Oncology,1994,12(7):1408-1414.
［24］FLEMING GF,FILIACI VL,BENTLEY RC,et al.Phase Ⅲ randomized trial of doxorubicin+cisplatin versus doxorubicin+24-h paclitaxel+filgrastim in endometrial carcinoma:a Gynecologic Oncology Group study［J］.Annals of Oncology,2004,15(8):1173-1178.
［25］ETHIER JL,DESAUTELS DN,AMIR E,et al.Is hormonal therapy effective in advanced endometrial cancer?A systematic review and meta-analysis［J］.Gynecologic Oncology,2017,147(1):158-166.
［26］BESTVINA CM,FLEMING GF.Chemotherapy for endometrial cancer in adjuvant and advanced disease settings［J］.Oncologist,2016,21(10):1250-1259.
［27］VAN WEELDEN WJ,LALISANG RI,BULTEN J,et al.Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer［J］.American Journal of Obstetrics and Gynecology,2021,225(4):407,e401-407,e416.
［28］JAMIESON A,HUVILA J,CHIU D,et al.Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death［J］.Modern Pathology,2023,36(4):100085.
［29］VERMIJ L,JOBSEN JJ,LEON-CASTILLO A,et al.Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry［J］.British Journal of Cancer,2023,128(7):1360-1368.
［30］周蓉,王益勤,鹿群,等.早期子宫内膜癌保留生育功能治疗专家共识（2022年版）［J］.中国妇产科临床杂志,2023,24(02):215-219. ZHOU R,WANG YY,LU Q,et al.Expert consensus on fertility preservation treatment for early endometrial cancer(2022 Edition)［J］.Chinese Journal of Clinical Obstetrics and Gynecology,2023,24(02):215-219.
［31］PIJNENBORG JMA,VAN WEELDEN WJ,REIJNEN C,et al.Redefining the position of hormonal therapy in endometrial cancer in the era of molecular classification［J］.Journal of Clinical Oncology,2024,42(1):8-12.
［32］VAN WEELDEN WJ,BIRKENDAHL PB,LALISANG RI,et al.The effect of progestin therapy in advanced and recurrent endometrial cancer:A systematic review and meta-analysis［J］.BJOG,2023,130(2):143-152.
［33］KONSTANTINOPOULOS PA,LEE EK,XIONG N,et al.A phase Ⅱ,two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer［J］.Journal of Clinical Oncology,2023,41(3):599-608.
［34］SLOMOVITZ BM,JIANG Y,YATES MS,et al.Phase Ⅱ study of everolimus and letrozole in patients with recurrent endometrial carcinoma［J］.Journal of Clinical Oncology,2015,33(8):930-936.
［35］SOLIMAN PT,WESTIN SN,IGLESIAS DA,et al.Everolimus,letrozole,and metformin in women with advanced or recurrent endometrioid endometrial cancer:A multi-center,single arm,phase Ⅱ study［J］.Clinical Cancer Research,2020,26(3):581-587.
［36］HEUDEL P,FRENEL JS,DALBAN C,et al.Safety and efficacy of the mTOR inhibitor,vistusertib,combined with anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial cancer:The VICTORIA multicenter,open-label,phase 1/2 randomized clinical trial［J］.JAMA Oncol,2022,8(7):1001-1009.
［37］GREEN AK,ZHOU Q,IASONOS A,et al.A phase Ⅱ study of fulvestrant plus abemaciclib in hormone receptor-positive advanced or recurrent endometrial cancer［J/OL］.Clinical Cancer Research,2024(2024-11-19)［2024-11-28］.https://doi.org/10.1158/1078-0432.CCR-24-1999.
［38］YONEMORI K,BONI V,MIN KG,et al.Imlunestrant,an oral selective estrogen receptor degrader,as monotherapy and combined with abemaciclib,in recurrent/advanced ER-positive endometrioid endometrial cancer:Results from the phase 1a/1b EMBER study［J/OL］.Gynecologic Oncology,2024,191:172-181.(2024-10-22)［2024-11-28］.https://doi.org/10.1016/j.ygyno.2024.10.006.
［39］COLON-OTERO G,ZANFAGNIN V,HOU X,et al.Phase Ⅱ trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers［J］.ESMO Open,2020,5(5):e000926.
［40］ENGELSEN IB,STEFANSSON IM,AKSLEN LA,et al.GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival［J］.American Journal of Obstetrics and Gynecology,2008,199(5):543,e541-547.
［41］SMITH D,STEWART CJR,CLARKE EM,et al.ER and PR expression and survival after endometrial cancer［J］.Gynecologic Oncology,2018,148(2):258-266.
［42］PERRONE E,CAPASSO I,DE FELICE F,et al.Back to the future:The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification［J］.European Journal of Cancer,2023,186:98-112.
［43］TANGEN IL,WERNER HM,BERG A,et al.Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions［J］.European Journal of Cancer,2014,50(17):3003-3010.
［44］ZHOU W,FRANC BL,DEMARTINI WB,et al.Estrogen receptor-targeted PET imaging for breast cancer［J］.Radiology,2024,312(2):e240315.
［45］DAGHER C,MANNING-GEIST B,ELLENSON LH,et al.Molecular subtyping in endometrial cancer:A promising strategy to guide fertility preservation［J］.Gynecologic Oncology,2023,179:180-187.
［46］CHUNG YS,WOO HY,LEE JY,et al.Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer［J］.American Journal of Obstetrics and Gynecology,2021,224(4):370,e371-370,e313.
［47］DA CRUZ PAULA A,DELAIR DF,FERRANDO L,et al.Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer［J］.Gynecologic Oncology,2021,161(2):535-544.
［48］ALAFRAIDI M,HOANG L,HOWITT BE,et al.The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile［J］.Histopathology,2024,85(4):660-670.
［49］VREDE SW,VAN WEELDEN WJ,BULTEN J,et al.Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer［J］.Gynecologic Oncology,2024,192:15-23.

Memo

Memo:
国家重点研发计划“生育健康及妇女儿童健康保障”重点专项（编号：2022YFC2704402）；National Natural Science Foundation of China(No.82172626);国家自然科学基金委员会面上项目（编号：82172626）；天津市卫生健康委员会重点学科专项（编号：TJWJ2022XK009）；天津市医学重点学科（专科）建设项目（编号：TJYXZDXK-031A）
Last Update: 1900-01-01